"A cocktail of these monoclonal antibodies, although it is aimed at solving the same problem - treating a patient who has already become infected with a new coronavirus - can be completely different, because these monoclonal antibodies will interact with different points in the S-protein," Gintsburg is quoted by RIA Novosti.
According to him, in order to understand which drug will be more effective, clinical trials will be conducted.
“In the fall, I hope, clinical trials will begin.
Hopefully, the first or second phase of testing will begin.
Various technologies are used to obtain these antibodies, the drug is already clinical.
They have slightly different properties.
Which property will be better and which drug will have advantages according to which technology, you can never say in advance, ”said Gunzburg.
The antibody-based drug will be administered in a dropper mode.
It is assumed that one patient will need to put them no more than two times.
“From the moment of infection, when he starts to get sick, he receives a drug that neutralizes the virus, during which time a person begins to develop his own antibodies, this is 7-10 days ... he began to recover.
And due to these antibodies, he held out until he developed his own, that's the point, ”the scientist explained.
At the same time, the head of the Gamaleya center expressed the opinion that a drug for the treatment of patients with coronavirus based on antibodies would be several times more expensive than a vaccine "in terms of production and in terms of the final price."